Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1562902A · 1 trial · 1 indication
Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was A/Indonesia/05/2005.
| Arm | Type | Description |
|---|---|---|
| 1562902A NP GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21. |
| 1562902A CP GROUP | EXPERIMENTAL | Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21. |
| Name | Type | Description |
|---|---|---|
| GSK1562902A | BIOLOGICAL | new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female aged 18 to 60 years at the time of the first vaccination. * Written informed consent obtained from the subject. * Good...
GSK1562902A is a monoclonal antibody being developed by GSK plc for influenza. It is an investigational drug studied in a Phase 3 clinical trial for the prevention or treatment of influenza. The drug has not been approved by regulatory authorities and remains in clinical development.
GSK1562902A is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for influenza, an infectious disease, but the exact antigen or protein it binds to is not specified.
GSK1562902A is developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research on this monoclonal antibody for influenza.
GSK1562902A is in Phase 3 clinical development for influenza. It is an investigational drug, meaning it has not been approved by regulatory agencies. The Phase 3 trial has been completed, but the drug is not yet available for commercial use.
GSK1562902A has one completed Phase 3 clinical trial with the identifier NCT00812981. This study, titled 'A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine,' enrolled 320 participants in Taiwan. The trial was randomized, double-blind, and controlled, involving healthy volunteers aged 18 years and older.